$43.140
+0.375 (+0.87%)終値時点
TRAX のニュース
TRAX のイベント
First Tracks Biotherapeutics Sells 6.1M Shares at $32.75 Each
First Tracks Biotherapeutics announced that it has entered into a securities purchase agreement to sell 6,106,870 shares of its common stock to a limited group of institutional investors in a private placement at a price of $32.75 per share. First Tracks Biotherapeutics anticipates approximately $200M in gross proceeds to the company before deducting placement agent fees and other expenses. Closing of the private placement is expected to occur on October 19, subject to the satisfaction of customary closing conditions. The private placement included participation from new and existing investors including Affinity Asset Advisors, LLC, First Light Asset Management, Sirenia Capital Management LP, TCGX, Trails Edge Capital Partners, Vestal Point Capital, a life sciences-focused institutional investor and multiple leading mutual funds. Leerink Partners, Piper Sandler, UBS Investment Bank and Wells Fargo Securities are acting as placement agents for the private placement.
Dow Rises While Nasdaq Falls
The major averages were mixed, with the Dow rising and the Nasdaq falling, as investors get ready for what is widely expected to be another strong corporate earnings season.The focus now shifts to third-quarter earnings, with JPMorgan Chase, Wells Fargo, Goldman Sachs and Citigroup set to report Tuesday. Analysts are expecting strong year-over-year earnings growth for S&P 500 companies, with AI-related spending and growth continuing to support the outlook. Investors also will be watching September inflation figures, with consumer and producer inflation reports set to hit late in the week.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Nvidiais in talks to either acquire or increase its investment in Reflection AI, FT reportsAmazonis in discussions to acquire AI startup Decart for $7B, WSJ reportsIonQagreed to acquire Elisity in an up to $1.3B all-stock transactionA Starbucksspokesperson told CNBC the company is not buying ChipotleBumbleis in advanced talks to go private at a $1B valuation, WSJ reports2. WALL STREET CALLS:Salesforcedouble upgraded to Buy from Underperform at BofAAdobedouble downgraded to Underweight from Overweight at Wells FargoRaymond James upgraded T-Mobileto Outperform, calls recent fears over competition from SpaceX"overblown"GoDaddydowngraded to Sector Perform at RBC CapitalTruist upgraded First Solarto Buy on strong pricing backdrop3. AROUND THE WEB:IntelCEO Lip-Bu Tan said that the costs of Chinese AI models have lowered, and adoption has been "very fast," Reuters reportsGTCR and Elliott Investment Management are in advanced talks to acquire car insurance software provider CCC Intelligent Solutions, and a deal could potentially be announced as soon as this week, Bloomberg reportsSynopsysis exploring partnerships with Chinese AI labs to develop AI-powered chip design tools for the Chinese market, Nikkei Asia reportsSVRN'stransformation from a small shipping company into a NEAR token treasury and SovereignAI business raises significant governance, dilution, valuation, and disclosure concerns, Fugazi Research tells investorsAnthropic CEO Dario Amodei sought additional computing capacity from Metaearlier this year, but after considering the request, Meta ultimately decided not to supply Anthropic with chips for now, WSJ says4. MOVERS:First Tracks Biotherapeuticsgains after reporting results from its Cohort 1 trial of ANB033AST SpaceMobileincreases after Deutsche Bank upgraded the stock to BuyMetawas higher after the company introduced the Muse Wonder seriesTTM Technologieslower after announcing plans to invest $400M to expand its capacity at four facilities in ChinaAmprius Technologiesfalls after filing an automatic mixed securities shelf5. EARNINGS/GUIDANCE:Bausch + Lomband Bausch Healthare expected to raise FY26 adjusted EBITDAEnovixreported preliminary Q3 results, with revenue beating consensusTormraised its outlook for FY26ASE Technologyreported Q3 revenue higher year-over-yearTSMCto report Q3 results on October 15INDEXES:The Dow rose 195.60, or 0.38%, to 51,850.55, the Nasdaq lost 120.27, or 0.44%, to 27,245.90, and the S&P 500 declined 4.30, or 0.06%, to 7,807.24.
Major Averages Mixed as Investors Eye Earnings Season
The major averages were mixed near noon as investors weigh rising oil prices and geopolitical risks against expectations for another strong corporate earnings season. Brent crude reached a roughly two-week high after deadly strikes on Riyadh's international airport over the weekend, while uncertainty surrounding the conflict involving Iran continues to cloud the outlook for global energy supplies.The focus now shifts to third-quarter earnings, with JPMorgan Chase, Wells Fargo, Goldman Sachs and Citigroup set to report Tuesday. Analysts are expecting strong year-over-year earnings growth for S&P 500 companies, with AI-related spending and growth continuing to support the outlook. Investors are also watching September inflation figures, with CPI due Wednesday and PPI and retail sales scheduled for Thursday.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Nvidiais in talks to either acquire or increase its investment in Reflection AI, FT reportsAmazonis in discussions to acquire AI startup Decart for $7B, WSJ reportsIonQagreed to acquire Elisity in an up to $1.3B all-stock transactionA Starbucksspokesperson told CNBC the company is not buying ChipotleIntelCEO Lip-Bu Tan said that the costs of Chinese AI models have lowered, and adoption has been "very fast," Reuters reports2. WALL STREET CALLS:Salesforcedouble upgraded to Buy from Underperform at BofAAdobedouble downgraded to Underweight from Overweight at Wells FargoRaymond James upgraded T-Mobileto Outperform, calls recent fears over competition from SpaceX"overblown"GoDaddydowngraded to Sector Perform at RBC CapitalTruist upgraded First Solarto Buy on strong pricing backdrop3. AROUND THE WEB:GTCR and Elliott Investment Management are in advanced talks to acquire car insurance software provider CCC Intelligent Solutions, and a deal could potentially be announced as soon as this week, Bloomberg reportsHSBCplans to phase out fixed-pay allowances for senior staff and instead give them a bigger portion of its compensation through bonuses, Bloomberg saysSynopsysis exploring partnerships with Chinese AI labs to develop AI-powered chip design tools for the Chinese market, Nikkei Asia reportsSVRN'stransformation from a small shipping company into a NEAR token treasury and SovereignAI business raises significant governance, dilution, valuation, and disclosure concerns, Fugazi Research tells investorsAnthropic CEO Dario Amodei sought additional computing capacity from Metaearlier this year, but after considering the request, Meta ultimately decided not to supply Anthropic with chips for now, WSJ says4. MOVERS:First Tracks Biotherapeuticsgains after reporting results from its Cohort 1 trial of ANB033AST SpaceMobileincreases after Deutsche Bank upgraded the stock to BuyC3 AIhigher after Northland upgraded the stock to OutperformTTM Technologieslower after announcing plans to invest $400M to expand its capacity at four facilities in ChinaAmprius Technologiesfalls after filing an automatic mixed securities shelf5. EARNINGS/GUIDANCE:Bausch + Lomband Bausch Healthare expected to raise FY26 adjusted EBITDAEnovixreported preliminary Q3 results, with revenue beating consensusTormraised its outlook for FY26ASE Technologyreported Q3 revenue higher year-over-yearTSMCto report Q3 results on October 15INDEXES:Near midday, the Dow was up 252.66, or 0.49%, to 51,907.61, the Nasdaq was down 60.01, or 0.22%, to 27,306.16, and the S&P 500 was up 2.59, or 0.03%, to 7,814.13.
First Tracks Biotherapeutics ANB033 Trial Results Show Significant Efficacy
First Tracks Biotherapeutics announced top-line results from Cohort 1 of ANB033's Phase 1b trial in celiac disease, or CeD. ANB033, an investigational, subcutaneously administered CD122 antagonist, is designed to inhibit the signaling of both IL-15 and IL-2 on immune cells. ANB033 demonstrated a statistically significant difference compared to placebo across key histologic endpoints, including least squares, or LS, mean change in villus height-to-crypt depth ratio, intraepithelial lymphocyte, or IEL, density, and VCIEL composite scale, as well as symptom endpoints using the Celiac Disease Symptom Diary, or CDSD. In the context of an intense gluten challenge, treatment with ANB033 not only prevented an increase in IEL density, but also protected against gluten-induced intestinal damage with changes in Vh:Cd ratio remaining below the threshold considered clinically meaningful. The randomized, placebo-controlled Phase 1b trial in CeD is evaluating subcutaneous ANB033 administered across two cohorts: Cohort 1, a 6-week study assessing prevention of gluten-induced intestinal damage and symptoms after a 14-day gluten challenge, and Cohort 2, assessing mucosal healing in patients with a broad range of histologic and symptom severity through 12 weeks. Cohort 1 evaluated 32 patients who completed dosing and the gluten challenge at Week 6. Patients received three subcutaneously administered loading doses of ANB033 or placebo at Week 0, Week 2, and Week 4, followed by a 14-day gluten challenge. The trial assessed safety and tolerability as well as key histologic and symptom endpoints used to measure clinical benefit with a primary analysis at Week 6. ANB033 achieved the key histologic efficacy endpoints of LS mean change from baseline in Vh:Cd ratio, IEL density, and VCIEL vs. placebo at Week 6. Using the Celiac Disease Symptom Diary, symptoms were assessed daily through the entire 14-day gluten challenge. The CDSD is a validated, patient-reported outcome measure that assesses the frequency and severity of five key celiac disease symptoms which are abdominal pain, bloating, nausea, diarrhea and tiredness. Placebo patients experienced a marked increase in symptoms consistent with an intense gluten challenge. ANB033 prevented an increase in symptoms throughout the entire gluten challenge. Overall, 47% of placebo patients and only 6% of ANB033 patients took permitted medications to mitigate their GI symptoms. Lower CDSD score on ANB033 vs. placebo, a statistically significant difference from the first day through the seventh day. Lower moderate-to-severe symptoms on ANB033 vs. placebo, a statistically significant difference from the first day through the twelfth day. ANB033 demonstrated a consistent, favorable safety and tolerability profile with no serious adverse events, no severe adverse events and no AEs leading to discontinuation.
First Tracks Anticipates Treating Four Indications by 2027
"First Tracks continues to execute against a broad development strategy for our potentially best-in-class CD122 antagonist, ANB033, and anticipates treating patients across four indications in 2027. We believe ANB033 is uniquely positioned to deliver differentiated clinical and biological outcomes across multiple immune-mediated diseases," said Daniel Faga, president and chief executive officer. "In celiac disease, FDA's Fast Track designation for ANB033 underscores both the urgency of the significant unmet need for patients and the potential of this program. We will report top-line data from Cohort 1 of the Phase 1b trial in Q4 2026, evaluating ANB033's potential to prevent gluten-induced mucosal injury. Cohort 2 of this study is enrolling patients with disease across a wide range of histologic and symptom severity at baseline with the goal of generating deeper insights into timing to mucosal healing and disease biology. We anticipate reporting these data in Q1 2027, followed by top-line data from our Phase 1b trial of ANB033 in eosinophilic esophagitis in Q3 2027."
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。